Eisai wins FDA nod for a drug to treat chemo-caused nausea

Eisai and partner Helsinn secured the FDA's blessing to market Akynzeo, a combination treatment designed to prevent nausea and vomiting among cancer patients undergoing chemotherapy. The long-acting drug combines palonosetron, approved in 2008 and sold by Eisai as Aloxi, with netupitant, a new agent. The former is designed to prevent nausea within the first 24 hours of chemo, while the latter provides relief for up to 5 days afterward. More from FiercePharma

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.